Wolverine (BPC-157 + TB-500)
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
What is it?
The “Wolverine stack” is the most popular recovery combination in the peptide world, and the logic behind it is clean: take the two best-known repair peptides — one that works locally and fast, one that works systemically — and run them together so you cover repair from both angles in a single shot. It’s named after the comic character who heals from anything, and it’s exactly what it sounds like: BPC-157 and TB-500, 5 mg of each, co-formulated in one vial.
This blend’s evidence base is its two components’ evidence — so the BPC-157 and TB-500 articles are the deep dives, and this page is the stack rationale, the combined protocol, and the honest status of “the two together.” The framing worth keeping is the same as always: this is a recovery accelerant layered on top of the inputs that actually rebuild tissue — sleep, protein, loading, patience. On that foundation, it’s a convenient, well-reasoned, popular tool.
What does it do in my body?
The rationale is genuinely sound on paper, which is why this pairing caught on with practitioners (one practitioner references originating the protocol; Bakri confirms “Wolverine = BPC-157 + TB-500” is the established street taxonomy). The two peptides hit different, complementary repair levers:
- BPC-157: the local repair signal. Drives angiogenesis (new blood vessels) via VEGF/VEGFR2 and activates the FAK–paxillin pathway so collagen-laying fibroblasts crawl into an injury and rebuild it. Acts fast and often near the injection site [PMID 18594781, 25415472].
- TB-500: the systemic coordinator. Sequesters actin to mobilize cells over distance, dials inflammation down via NF-κB/TGF-β suppression, and reduces fibrosis/scarring. Longer-acting and body-wide [PMID 22074294, 36580759].
Local plumbing and FAK-paxillin healing (BPC-157) plus systemic cell-migration and anti-inflammation (TB-500): the migrating cells TB-500 mobilizes need the blood supply and matrix BPC-157 helps build, so the mechanisms genuinely dovetail. That complementary logic is why this is the default recovery stack.
The honest framing: the complementary-mechanism case is a strong rationale — it’s how the combination was reasoned into existence — and it’s well grounded in each peptide’s separate biology. It hasn’t been measured as a combination (see below), so treat the “synergy” as a well-motivated hypothesis backed by heavy real-world use, not a quantified finding.
How can it help me?
- Best fit: The popular all-in-one recovery stack — local + systemic repair in a single shot
- Where the science stands: Each component has its own preclinical + early-human record — BPC-157 now has published human pilots incl. intra-articular knee pain [PMID 34324435] (see component pages); no dedicated study of the two co-administered
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
The blend’s tolerability is each component’s profile run together, and both are well-tolerated.
- Injection-site itching / irritation — most common; rotate sites, clean technique.
- Mood / dopaminergic effects (from the BPC-157 component) — occasional anxiety or flattened mood; lower the dose or pause if noticed.
- Mild headache or lethargy (from the TB-500 component) — occasional, transient.
- Cancer caution — BPC-157 and TB-500 have meaningfully different profiles here. BPC-157 data is reassuring (melanoma cell study found reduced proliferation; vessel growth is injury-contextualized). TB-500/Tβ4 has mechanism-grounded concern backed by real data in animal and human-tissue studies (see “What the research shows” above for the full breakdown). Active or recent cancer history is a substantive reason to reconsider this stack; KPV or Thymosin Alpha-1 are practitioner-cited alternatives. The key distinction for TB-500: published cancer data measures endogenous tumor-produced Tβ4, not administered TB-500 — the extrapolation to exogenous dosing is plausible but untested. Pregnancy commonly listed as a contraindication.
As with the single agents, the largest real-world variable is product quality — whether the vial actually contains both peptides at the stated dose and identity. A fixed-ratio blend makes a third-party COA especially valuable, because it verifies both components at once.
Regulatory status: Not FDA-approved. Both components are banned by WADA and on the U.S. DoD prohibited list; BPC-157’s acetate form was removed from FDA compounding Category 2 in April 2026 but is not yet on Category 1. The combination itself has no separate regulatory recognition. Sold legally as a research chemical, “not for human consumption.”
Part 1 — How to reconstitute it
What's used: bacteriostatic water (sterile, preserved water the powder is mixed with) and a separate, larger reconstitution syringe used only for mixing — not the small syringe used for administration.
Reconstitution (objective math, this 5mg/5mg vial). Add 2 mL bacteriostatic water → 2.5 mg/mL of EACH peptide (2,500 mcg/mL each). A 500-mcg-each dose = 0.2 mL = 20 units on a U-100 insulin syringe, delivering 500 mcg BPC-157 + 500 mcg TB-500 in one shot. Add water slowly down the vial wall, swirl gently (never shake), refrigerate reconstituted.
How it's mixed
- The vial is tilted and the bacteriostatic water is added slowly down the inside glass wall — not squirted straight onto the powder.
- It is swirled gently to dissolve. It is never shaken — shaking can damage the peptide.
- The reconstituted vial is stored refrigerated and out of light.
- Reconstituted peptides are commonly used within a few weeks, inside the beyond-use window the source specifies — that window varies by peptide.
The free reconstitution calculator does the concentration math for any vial size and water volume, including the equivalent units on an insulin syringe.
Part 2 — Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
Administration as reported. Reported practice is subcutaneous administration (into the fat just under the skin) using a 0.3 mL U-100 insulin syringe, with sites rotated.
Community-standard protocol (mirrors the single-agent conventions):
- Dose: ~500 mcg of each per dose (20 units from this vial).
- Frequency: once daily is the common all-in-one cadence; some run AM/PM early in a cycle. Because TB-500 is longer-acting, daily-to-every-other-day works once the cycle is established.
- Cycle: a focused 4–8 week repair block, 8 weeks on / off, run to the recovery goal.
One practical limitation worth knowing: because both peptides come out of the same vial in a fixed 1:1 ratio, you can’t titrate them independently. If you want to run, say, more BPC-157 locally near an injury and less TB-500 systemically, separate vials give you that control — the blend trades flexibility for convenience and a single injection. The all-in-one is the simplest path; separate BPC-157 + TB-500 vials are the flexible path. Many users who want the denaturing question off the table also prefer separate vials dosed from two syringes.
What should I avoid combining — and what's synergistic?
Stacking further. Adding GHK-Cu turns the Wolverine pairing into GLOW (collagen/skin layer); adding KPV makes it KLOW (immune/anti-inflammatory layer). It also pairs naturally alongside a Retatrutide fat-loss phase for joint and recovery support (Williams and Jones both endorse BPC/TB alongside Reta).
Where do people source this?
A physician-prescribed route exists for Wolverine (BPC-157 + TB-500). The Wolverine stack (BPC-157 + TB-500) is available through licensed US telehealth providers: an online intake, review by a licensed physician, and — if prescribed — compounding at a licensed 503A/503B pharmacy with delivery to the door. See the prescribed Wolverine (BPC-157 + TB-500) option →
OHM does not sell or handle any compound. Research-use-only material is also sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. Whatever the route, the supply chain is the real risk: only consider sources that publish batch-level third-party Certificates of Analysis.
| Class | Two-peptide recovery blend: BPC-157 (5 mg) + TB-500 (5 mg) in one vial |
| Mechanism (one line) | Pairs BPC-157’s local angiogenesis + FAK–paxillin repair with TB-500’s systemic actin-driven cell migration and anti-inflammatory action — repair from two complementary angles |
| Route / frequency | Subcutaneous; both peptides dose together from the fixed-ratio vial |
| Evidence base | Each component has its own preclinical + early-human record — BPC-157 now has published human pilots incl. intra-articular knee pain [PMID 34324435] (see component pages); no dedicated study of the two co-administered |
| Safety record | Both components well-tolerated individually; mild injection-site reactions most common |
| Regulatory status | Not FDA-approved; both components WADA-banned |
| Best-fit user | The popular all-in-one recovery stack — local + systemic repair in a single shot |
What it is
The “Wolverine stack” is the most popular recovery combination in the peptide world, and the logic behind it is clean: take the two best-known repair peptides — one that works locally and fast, one that works systemically — and run them together so you cover repair from both angles in a single shot. It’s named after the comic character who heals from anything, and it’s exactly what it sounds like: BPC-157 and TB-500, 5 mg of each, co-formulated in one vial.
This blend’s evidence base is its two components’ evidence — so the BPC-157 and TB-500 articles are the deep dives, and this page is the stack rationale, the combined protocol, and the honest status of “the two together.” The framing worth keeping is the same as always: this is a recovery accelerant layered on top of the inputs that actually rebuild tissue — sleep, protein, loading, patience. On that foundation, it’s a convenient, well-reasoned, popular tool.
How it works
The rationale is genuinely sound on paper, which is why this pairing caught on with practitioners (one practitioner references originating the protocol; Bakri confirms “Wolverine = BPC-157 + TB-500” is the established street taxonomy). The two peptides hit different, complementary repair levers:
- BPC-157: the local repair signal. Drives angiogenesis (new blood vessels) via VEGF/VEGFR2 and activates the FAK–paxillin pathway so collagen-laying fibroblasts crawl into an injury and rebuild it. Acts fast and often near the injection site [PMID 18594781, 25415472].
- TB-500: the systemic coordinator. Sequesters actin to mobilize cells over distance, dials inflammation down via NF-κB/TGF-β suppression, and reduces fibrosis/scarring. Longer-acting and body-wide [PMID 22074294, 36580759].
Local plumbing and FAK-paxillin healing (BPC-157) plus systemic cell-migration and anti-inflammation (TB-500): the migrating cells TB-500 mobilizes need the blood supply and matrix BPC-157 helps build, so the mechanisms genuinely dovetail. That complementary logic is why this is the default recovery stack.
The honest framing: the complementary-mechanism case is a strong rationale — it’s how the combination was reasoned into existence — and it’s well grounded in each peptide’s separate biology. It hasn’t been measured as a combination (see below), so treat the “synergy” as a well-motivated hypothesis backed by heavy real-world use, not a quantified finding.
What the research shows
The combination itself: a PubMed search returns no published study of BPC-157 + TB-500 co-administered — human, animal, or in-vitro — as of mid-2026. There are no combination PK or interaction studies. So the blend’s evidence is assessed component-by-component, and the “stack” is a practitioner/real-world construct supported by extensive anecdotal use rather than a trial of the pair. That’s the straight status — stated once, plainly.
Each component, though, brings a real body of evidence (full detail on the component pages):
- BPC-157: a deep, consistent preclinical record across tendon (Achilles transection, [PMID 18594781]), ligament (MCL, [PMID 20225319]), gut (ulcer protection, [PMID 7904712]), and vascular models, with independent reviews [PMID 30915550, 40756949] confirming “consistently positive and prompt healing effects.” Early human use now includes published small pilots: intra-articular knee-pain [PMID 34324435] — directly relevant to this stack’s joint/recovery use — plus an interstitial-cystitis pilot [PMID 39325560], an IV-infusion safety pilot [PMID 40131143], and placebo-controlled Phase 1/2 ulcerative-colitis enema trials. Safety record clean.
- TB-500 / Thymosin Beta-4 — coherent preclinical biology (actin/migration, angiogenesis, anti-fibrosis [PMID 22074294, 36580759, 27450736]) plus human data for clinical-grade Tβ4: an rhTB4 STEMI RCT (overall non-significant, positive early-dosing subgroup, [PMID 41229390]), and Phase 2 eye-drop and dermal-wound trials [PMID 30063853, 27450738].
Cancer-risk distinction: BPC-157 and TB-500 tell different stories here. Both peptides have mechanisms touching angiogenesis and cell migration, so the cancer-risk question is legitimate. The data, looked at specifically, runs differently for each component.
BPC-157 — the evidence is reassuring. The one direct test of BPC-157 on cancer cells found the opposite of what the concern predicts: in melanoma cell culture, BPC-157 reduced the fraction of actively dividing cells by up to 55%. A second study found BPC-157’s angiogenic effect is injury-contextual — it promoted vessel growth in wounded tissue but showed essentially no effect on normal, uninjured cells. No published study in any model has found BPC-157 promoting tumor growth. The concern remains mechanism-level; the actual data runs the other direction. The Sikiric/Seiwerth research-group concentration is a limitation worth noting — independent replication of the cancer-relevant findings specifically hasn’t occurred.
TB-500 — the data is more concerning, with one critical nuance. Three published studies show a real connection between Tβ4 and cancer behavior. In a mouse melanoma model, elevated TB-4 produced tumors roughly 63% larger and more than 4× as many lung metastases versus controls, with approximately 4.4× more tumor blood vessels. In human colorectal cancer tissue, TB-4 levels correlated with metastatic spread. And Tβ4 promotes colon cancer cell migration via ILK/IQGAP1/Rac1 signaling in cell culture. These findings are real and grounded. The essential nuance: every one of these studies measures tumor-produced Tβ4, not administered TB-500. Tumors endogenously upregulate Tβ4 as part of their own invasion machinery — that’s why tumors with more of their own Tβ4 grow faster. Whether exogenously administered TB-500 replicates this in a person with a pre-existing tumor hasn’t been formally studied. The gap between “tumor overexpresses TB-4 → worse cancer” and “healthy person administers TB-500 → cancer grows” is real and important. Still, the mechanism is genuine, and the concern isn’t dismissible, especially in someone with known tumor activity.
Practical takeaway. For anyone with active or recent cancer history, the TB-500 component carries mechanism-grounded caution — the data is real even if the administered-vs-tumor-produced distinction reduces the alarm. KPV (available via KLOW) or Thymosin Alpha-1 are practitioner-cited alternatives for the healing and immune-support use case in that population, with no equivalent cancer-risk concern. For healthy individuals with no cancer history, this is a genuine-but-theoretical caution for TB-500 and a nearly non-existent concern for BPC-157 based on the data as it stands.
Where experts land: one practitioner treats the combined repair effect as obvious and reliable from his clinical use and originated the protocol; Bakri treats the pairing as plausible and widely used but notes (as for any peptide combo) the open question of whether co-mixing two peptides in one vial risks denaturing. Both endorse the stack as a real-world tool; they differ on how much certainty to attach to “synergy” beyond each component’s own action.
Real-world protocol
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
Reconstitution (objective math, this 5mg/5mg vial). Add 2 mL bacteriostatic water → 2.5 mg/mL of EACH peptide (2,500 mcg/mL each). A 500-mcg-each dose = 0.2 mL = 20 units on a U-100 insulin syringe, delivering 500 mcg BPC-157 + 500 mcg TB-500 in one shot. Add water slowly down the vial wall, swirl gently (never shake), refrigerate reconstituted.
Community-standard protocol (mirrors the single-agent conventions):
- Dose: ~500 mcg of each per dose (20 units from this vial).
- Frequency: once daily is the common all-in-one cadence; some run AM/PM early in a cycle. Because TB-500 is longer-acting, daily-to-every-other-day works once the cycle is established.
- Cycle: a focused 4–8 week repair block, 8 weeks on / off, run to the recovery goal.
One practical limitation worth knowing: because both peptides come out of the same vial in a fixed 1:1 ratio, you can’t titrate them independently. If you want to run, say, more BPC-157 locally near an injury and less TB-500 systemically, separate vials give you that control — the blend trades flexibility for convenience and a single injection. The all-in-one is the simplest path; separate BPC-157 + TB-500 vials are the flexible path. Many users who want the denaturing question off the table also prefer separate vials dosed from two syringes.
Stacking further. Adding GHK-Cu turns the Wolverine pairing into GLOW (collagen/skin layer); adding KPV makes it KLOW (immune/anti-inflammatory layer). It also pairs naturally alongside a Retatrutide fat-loss phase for joint and recovery support (Williams and Jones both endorse BPC/TB alongside Reta).
Side effects & management
The blend’s tolerability is each component’s profile run together, and both are well-tolerated.
- Injection-site itching / irritation — most common; rotate sites, clean technique.
- Mood / dopaminergic effects (from the BPC-157 component) — occasional anxiety or flattened mood; lower the dose or pause if noticed.
- Mild headache or lethargy (from the TB-500 component) — occasional, transient.
- Cancer caution — BPC-157 and TB-500 have meaningfully different profiles here. BPC-157 data is reassuring (melanoma cell study found reduced proliferation; vessel growth is injury-contextualized). TB-500/Tβ4 has mechanism-grounded concern backed by real data in animal and human-tissue studies (see “What the research shows” above for the full breakdown). Active or recent cancer history is a substantive reason to reconsider this stack; KPV or Thymosin Alpha-1 are practitioner-cited alternatives. The key distinction for TB-500: published cancer data measures endogenous tumor-produced Tβ4, not administered TB-500 — the extrapolation to exogenous dosing is plausible but untested. Pregnancy commonly listed as a contraindication.
As with the single agents, the largest real-world variable is product quality — whether the vial actually contains both peptides at the stated dose and identity. A fixed-ratio blend makes a third-party COA especially valuable, because it verifies both components at once.
Regulatory status
Not FDA-approved. Both components are banned by WADA and on the U.S. DoD prohibited list; BPC-157’s acetate form was removed from FDA compounding Category 2 in April 2026 but is not yet on Category 1. The combination itself has no separate regulatory recognition. Sold legally as a research chemical, “not for human consumption.”
Sources
No combination studies exist; sources are the component literatures — see BPC-157 and TB-500 for full lists.
- (PMIDs 18594781, 20225319, 7904712, 25415472, 30915550, 40756949; human pilots 34324435, 39325560, 40131143) and (PMIDs 41229390, 22074294, 36580759, 27450736, 30063853, 27450738).
- confirms 0 combination records.
- the three new BPC-157 human pilots and the Mendias 2026 gray-market purity preprint (both components tested).
- (lot BPTB32, 99.23%).
- Video digests: one practitioner BPC-157 (2026-06-02), Huberman/Bakri (2026-06-01, Wolverine/GLOW sections).
- Cancer-specific sources (added 2026-07-14, from ):
- BPC-157 melanoma cell study: Radeljak, Seiwerth & Sikiric 2004, 15277704
- BPC-157 injury-specific angiogenesis: 20388964
- TB-4 mouse melanoma model: Cha, Jeong & Kleinman 2003, 14625258, JNCI
- TB-4 human colorectal cancer correlation: Wang et al. 2004, 15235586, Oncogene
- TB-4 colon cancer migration: Tang et al. 2011, 21621326, Cancer Letters
Related: BPC-157 · TB-500 · GLOW · KLOW · Retatrutide.
Sources & references
No combination studies exist; sources are the component literatures — see BPC-157 and TB-500 for full lists.
- (PMIDs 18594781, 20225319, 7904712, 25415472, 30915550, 40756949; human pilots 34324435, 39325560, 40131143) and (PMIDs 41229390, 22074294, 36580759, 27450736, 30063853, 27450738).
- confirms 0 combination records.
- the three new BPC-157 human pilots and the Mendias 2026 gray-market purity preprint (both components tested).
- (lot BPTB32, 99.23%).
- Video digests: one practitioner BPC-157 (2026-06-02), Huberman/Bakri (2026-06-01, Wolverine/GLOW sections).
- Cancer-specific sources (added 2026-07-14, from ):
- BPC-157 melanoma cell study: Radeljak, Seiwerth & Sikiric 2004, 15277704
- BPC-157 injury-specific angiogenesis: 20388964
- TB-4 mouse melanoma model: Cha, Jeong & Kleinman 2003, 14625258, JNCI
- TB-4 human colorectal cancer correlation: Wang et al. 2004, 15235586, Oncogene
- TB-4 colon cancer migration: Tang et al. 2011, 21621326, Cancer Letters
Related: BPC-157 · TB-500 · GLOW · KLOW · Retatrutide.
Community experience reports
Anecdotal — real-world reports from the peptide community, not clinical evidence. Presented alongside the graded science above, not as a substitute for it.
Companion raw digest: Evidence tier: throughout Last updated: 2026-07-10 Cross-refs:
[BPC-157](/peptides/bpc-157/)·[TB-500](/peptides/tb-500/)·*glow-blend*·*klow-blend*
Who reports the strongest results
People with chronic, treatment-resistant soft-tissue injuries — the injuries that didn’t respond to physical therapy, PRP, corticosteroids, and rest. Wolverine (BPC-157 + TB-500) is the community’s gold standard for healing musculoskeletal damage that conventional medicine couldn’t fix.
What the community actually says
The combination’s reputation
BPC-157 + TB-500 is the most used peptide combination for injury healing in the community. Its “Wolverine” branding captures the community’s experience: this is what makes you heal fast when nothing else has worked.
Why the combination outperforms either alone:
- BPC-157: Tendon-specific local action; nerve regeneration; gut healing; strongest when injected near the injury
- TB-500: Systemic soft-tissue repair; muscle fiber healing; works without precise injection location; cardiovascular endurance benefit
Together: different mechanisms, different tissue targets, complementary coverage of the full musculoskeletal picture.
The critical community warning
“Pain drops faster than structural integrity returns — don’t rush back to training.”
This appears in virtually every Wolverine thread on every forum. Multiple documented re-injury cases from users who returned to full training when pain disappeared (weeks 2–3) but before structural healing was complete (weeks 4–6). Use objective functional assessment (strength, range of motion), not pain disappearance, as the readiness signal.
Protocol as used by the community
BPC-157: 250–500 mcg per injection, 1–2× daily; local injection near injury or SubQ systemic
TB-500: 2–2.5 mg SubQ or IM, 2× per week during loading (4–6 weeks); 1–2 mg/week maintenance
Mixing: Both can be injected in the same syringe — community confirms compatibility
Injection approach: Hybrid is most recommended — systemic SubQ for TB-500; local injection for BPC-157 when site is accessible. For diffuse or multi-site injuries: both systemic.
Cycle: 6-week loading → 6-week maintenance → 8–12 weeks off
Non-response (~40%) and why
- Product quality — the dominant cause; BPC-157 is frequently counterfeited or underdosed
- Underdosing TB-500 during loading
- Too short a cycle — stopping before week 6
- Wrong injury type — bone and articular cartilage respond less than soft tissue
Source quality is the single most important variable for this combination.
No human RCTs
BPC-157 and TB-500 have extensive animal model data but no completed human RCTs. Community position: absence of RCTs is a funding gap, not evidence of inefficacy. The mechanism is established in animal models; the anecdotal evidence is extensive.
Side effects
Both components are mild individually. No significant combination interaction effects reported. See [BPC-157](/peptides/bpc-157/) and [TB-500](/peptides/tb-500/) for component-specific profiles.
Wolverine vs GLOW vs KLOW
| Blend | Components | Best for |
|---|---|---|
| Wolverine | BPC-157 + TB-500 | Musculoskeletal healing; the foundation |
| GLOW | BPC-157 + TB-500 + GHK-Cu | Healing + skin/cosmetic benefits |
| KLOW | BPC-157 + TB-500 + KPV + GHK-Cu | Healing + gut inflammation + skin |
Cross-references
[BPC-157](/peptides/bpc-157/)— component detail and solo community reports[TB-500](/peptides/tb-500/)— component detail and solo community reports*glow-blend*— Wolverine + GHK-Cu*klow-blend*— Wolverine + GHK-Cu + KPV